Cancer prevalence in the subcategories of the indeterminate class III (AUS/FLUS) of the Bethesda system for thyroid cytology: a meta-analysis.
Anna CrescenziAndrea PalermoPierpaolo TrimboliPublished in: Journal of endocrinological investigation (2021)
The overall cancer rate found in the Bethesda III ranged more largely than that originally estimated (10-30%) and varied among any scenarios. These evidence-based data represent a reference for the clinical management of these patients.
Keyphrases
- fine needle aspiration
- papillary thyroid
- end stage renal disease
- squamous cell
- ultrasound guided
- ejection fraction
- newly diagnosed
- chronic kidney disease
- climate change
- risk factors
- prognostic factors
- peritoneal dialysis
- high grade
- lymph node metastasis
- machine learning
- big data
- young adults
- artificial intelligence
- patient reported